Capricor Therapeutics (CAPR) Receives FDA Rejection of Deramiocel Application

Capricor Therapeutics (CAPR) received an FDA rejection for its Deramiocel application, citing insufficient evidence. The company has $198.5M in cash, funding at least 12 months of operations. The FDA's Complete Response Letter is a setback for Capricor's lead candidate, and the company will assess next steps.

Original reporting
Published Nov 21, 2026, 12:55 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 21, 2026, 12:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Capricor Therapeutics (CAPR) Receives FDA Rejection of Deramiocel Application — source image
Decision brief

The 30-second read

$CAPRBearishMed
01

Why it matters

The FDA CRL represents a material regulatory setback, likely prompting short‑term price decline and heightened volatility.

02

Market read

Regulatory outcome directly affects CAPR's valuation and may influence peer biotech stocks awaiting FDA decisions.

03

What to watch

The company's cash runway of $198.5M may allow continued development without immediate financing pressure.

Relevance 8/10Novelty 8/10Timing: today

Background

Capricor Therapeutics (CAPR) is a Nasdaq‑listed biotech focused on cell‑based therapies. The Deramiocel candidate targets a rare disease indication.

Company-level read

Ticker impact

$CAPRBearishHigh confidence
Context

FDA issued a Complete Response Letter rejecting Capricor Therapeutics' Deramiocel application, citing insufficient efficacy evidence.

Expected impact

likely pressure as the market prices in the FDA denial

Evidence & confidence

Regulatory denials for biotech candidates typically trigger immediate sell‑offs, especially for cash‑burning microcaps.

Market effects

May dampen sentiment for late‑stage biotech pipelines and increase scrutiny on similar cell‑therapy candidates.

Limited to US biotech sector; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

If Capricor can quickly address FDA concerns, the stock could rebound on a potential resubmission.

Key entities

  • Capricor Therapeutics

    Biotech firm developing Deramiocel.

  • U.S. Food and Drug Administration

    Issued the Complete Response Letter rejecting the application.

Related articles

$CAPRHigh

Why is Capricor Therapeutics stock surging today?

Capricor Therapeutics (CAPR) stock rose 10% pre-market ahead of the FDA's November 22, 2026 decision on deramiocel, a therapy for Duchenne muscular dystrophy. Analysts JonesTrading and Oppenheimer upgraded CAPR, citing potential approval and peak sales of $2.3B. Despite market downturns, CAPR's surge is driven by FDA anticipation and clinical data.